Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.
Roche is not ready to throw in the towel with its Huntington’s disease candidate, tominersen, despite a Phase III failure, and is to start a new trial in the hope it could work in a subgroup of patients.
The Swiss pharma company halted dosing in its Phase III GENERATION HD1 study in March 2021 after it failed to...
Oral RNA splicing modulator has gone into a Phase II/III trial
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.
First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.
